ContraFect (CFRX) Stock Analysis

What ContraFect does

ContraFect Corporation is a biotechnology firm operating at the clinical stage, dedicated to the discovery and development of innovative therapeutic proteins and antibodies. Its primary mission is to address life-threatening and drug-resistant infectious diseases within the United States. The company's most advanced candidate, Exebacase, a specialized enzyme known as a lysin, is currently undergoing Phase III clinical trials. This drug aims to treat bacteremia caused by Staphylococcus aureus. Beyond Exebacase, ContraFect is also progressing CF-296, an engineered lysin designed to combat invasive Staphylococcus aureus infections. These include challenging biofilm-related infections affecting prosthetic joints and indwelling medical devices, as well as osteomyelitis. Furthermore, CF-370, an investigational anti-bacterial therapy, has entered Phase 1 clinical trials. It targets a range of Pseudomonas aeruginosa infections, such as ventilator-associated pneumonia, bloodstream infections, complex urinary tract infections, and infections arising from surgery. In an effort to expand patient access, ContraFect has launched a program providing Exebacase for individuals with persistent methicillin-resistant Staphylococcus aureus (MRSA) bacteremia who are also suffering from COVID-19. A licensing agreement with The Rockefeller University further supports its efforts to identify novel lysin therapeutic compounds effective against gram-negative pathogens. ContraFect Corporation was founded in 2008 and maintains its headquarters in Yonkers, New York.

Key metrics

ETFs linked to CFRX

Broad-market and Healthcare sector ETFs an investor holding ContraFect is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how CFRX fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for ContraFect?

ContraFect trades under the ticker CFRX on NASDAQ.

Which exchange is CFRX listed on?

CFRX is listed on NASDAQ.

What sector does ContraFect operate in?

ContraFect is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze CFRX in a portfolio?

PortView shows CFRX's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.